Cell-Free Metabolic Engineering Patents: Leaders & Trends 2026
A data-backed look at 372 cell-free metabolic engineering and biosynthesis patent families: who holds the core chemistry, how filing activity has shifted since its 2017 peak, and where the technology white space sits.
Filing growth = 2021 (22 records) → 2024 (10); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 372 records in scope (CR5), not the ranked leaders only.
What this landscape covers
This landscape tracks 372 patent families published between 2015 and mid-2026 that claim cell-free metabolic engineering, cell-free biosynthesis or cell-free biomanufacturing — systems that build target molecules using enzymes, lysates or extracts outside a living cell rather than inside engineered microorganisms. The scope includes both the classic fermentation-and-enzyme chemistry that underlies decades of small-molecule production and the newer cell-free transcription-translation (TX-TL) platforms built for faster, more controllable synthesis.
Filing activity peaked in 2017 and the field is dominated by fermentation and microbial-engineering claims, with a smaller but distinct cluster of records covering therapeutic and peptide applications built on cell-free platforms.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The 372 records in scope span a decade of filing activity, from an early peak to a still-filling-in recent tail, across a technology mix concentrated in fermentation and microbial engineering.
Filing activity, 2017-2026
Filings peaked at 24 in 2017 and had fallen to 22 by 2021 and 10 by 2024, a 55% decline over that three-year span. 2025 and 2026 figures are still incomplete because publication lags filing by roughly 18 months, so the most recent years should not be read as a continued fall.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition by IPC subclass
Fermentation and enzymatic synthesis (C12P) and microorganism/genetic-engineering claims (C12N) each cover well over half of the 372 records in scope, at 66.1% and 62.6% respectively. Medicinal-preparation (A61K, 27.2%) and peptide/protein (C07K, 22.0%) claims form a secondary tier, with heterocyclic, carbocyclic and microorganism-index classes trailing further behind. Because records can carry multiple classes, these shares add up to more than 100%.
Shares are the percentage of the 372 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-Free Biomanufacturing: Cell-Free Metabolic Engineering Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cell-free biomanufacturing: cell-free metabolic engineering patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in the field
Methods and Apparatus for Cell-Free Microfluidic-Assisted Biosynthesis (US20160002611A1)
A trans-disciplinary system for cell-free biosynthesis combines a cell-free transcription-translation (TX-TL) tool with modular, generalizable microfluidic architectures. Modular plasmid libraries program bacterial cell-free TX-TL systems, with each plasmid holding one gene or operon under a shared promoter so enzyme-synthesis stoichiometry tracks plasmid ratios. A separate microfluidic component enables high-throughput mixing and matching of gene units.Filed by the Regents of the University of Minnesota, 7 January 2016.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4346227A | ML-236B Derivatives and their preparation | 2,096 |
| 2 | US4410629A | ML-236B Derivatives and their preparation | 509 |
| 3 | US4537859A | Process for preparing 3-hydroxy-ML-236B derivatives known as M-4 and M-4' | 500 |
| 4 | US4448979A | ML-236B Derivatives | 168 |
| 5 | CN109988801A | 一种用于体外生物反应体系的新型的高效的能源再生体系(BES)、试剂盒及制备方法 | 71 |
| 6 | GB2077264A | ML-236b derivatives and their preparation | 64 |
| 7 | WO2006063355A2 | Cell free biosynthesis of high-quality nucleic acid and uses thereof | 48 |
| 8 | US20160298151A1 | Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's inter… | 44 |
| 9 | WO2017031399A1 | Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis an… | 43 |
| 10 | US20020039771A1 | Method for producing complex multienzymatical, storage resistant reaction mixtures and use thereof | 32 |
Ranked by citation count within the searched corpus; older filings accumulate more citations by nature, so treat this as a signal of influence rather than current commercial importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for strategy
Four figures from the dataset matter more than the rest for anyone deciding where to file, litigate, or build next in cell-free biomanufacturing.
Ownership is concentrated but not closed
The top 5 ranked assignees hold 32.0% of all 372 records in scope, and the top 10 hold 50.3%. That leaves roughly half the field to a long tail across the remaining 90 ranked companies, which is where narrower design-around claims tend to originate.
Read the recent years cautiously
Filings fell from 22 in 2021 to 10 in 2024, a 55% drop across the only window that can currently be treated as complete. Publication lags filing by roughly 18 months, so 2025 and 2026 figures are not yet reliable evidence of a continuing trend.
Fermentation chemistry anchors the field
C12P (fermentation and enzymatic synthesis) and C12N (microorganisms and genetic engineering) each cover more than 60% of the 372 records in scope. Downstream classes like heterocyclic and carbocyclic compounds sit under 14%, marking the comparatively open branches.
US and Europe carry most of the volume
The United States (87) and the European Patent Office (69) receive far more filings than WIPO/PCT (36), India (27), China (23) or Canada (19). Applicants weighing secondary jurisdictions should check these smaller offices individually rather than assume coverage follows automatically.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-free biomanufacturing: cell-free metabolic engineering patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Cytogenix Inc | VAZQUEZ FRANK | 4 |
| Cytogenix Inc | SKOLNICK MALCOLM | 4 |
| Cytogenix Inc | KENDIRGI FREDERIC | 4 |
| Cytogenix Inc | CHEN YIN | 4 |
| Roche Diagnostics GmbH | SCHELS HANS | 3 |
| Roche Diagnostics GmbH | Boehringer Mannheim GmbH | 2 |
| Roche Diagnostics GmbH | REICHHUBER ROLF | 2 |
| Roche Diagnostics GmbH | METZLER THOMAS | 2 |
Ten co-assignee pairs appear in the dataset, with the strongest clusters all built around Cytogenix and named individual inventors, each pair appearing four times — a signature of a small, tightly collaborating inventor group rather than broad cross-company partnership.
Taking this further
The figures here identify where the field is concentrated and where it is thin. Turning that into a filing or licensing decision means looking at the specific claims behind the numbers.
Check freedom to operate against the core chemistry cluster
The ML-236B derivative family carries the field's highest citation counts and the broadest early compound-preparation scope. Any small-molecule cell-free route should be checked against this cluster before filing.
Explore the citation network in EurekaScope a claim into the under-claimed branches
Heterocyclic and carbocyclic compound classes sit well under 15% of records, well behind the fermentation and microbial core. That gap is where a narrower, defensible claim is more likely to clear.
Draft and test claims in EurekaTrack the long tail of single-filing entrants
Half the field sits outside the top 10 ranked assignees. Watching new entrants in that tail is often the earliest signal of where the next wave of TX-TL or extract-based filings will land.
Set up assignee monitoring in EurekaFrequently asked questions
The assignee ranking covers 100 companies and institutions across the 372 records in scope, with the leader holding 39 records and the fifth-place holder 18. The top 5 combined account for 32.0% of all 372 records, and the top 10 for 50.3%, so roughly half the field is held by a long tail of smaller filers. This mix of concentration and a long tail is typical of a field that has a strong foundational chemistry cluster alongside newer cell-free-system entrants.
Filings peaked at 24 in 2017 and fell to 10 by 2024, a 55% decline across the 2021-2024 window using the only complete recent years available. Data for 2025 and 2026 is still incomplete because patent publication typically lags actual filing by around 18 months, so those years understate real activity and should not be read as confirming a continued decline. The safest reading is that filing activity cooled from its 2017 peak but the most recent trend is not yet fully visible.
Fermentation and enzymatic synthesis claims (IPC class C12P) appear in 66.1% of the 372 records in scope, and microorganism and genetic-engineering claims (C12N) in 62.6%, making these the two dominant technical areas by a wide margin. Medicinal preparations (A61K, 27.2%) and peptide/protein chemistry (C07K, 22.0%) form a clear second tier. Heterocyclic compounds, carbocyclic compounds and the microorganism index class each sit in the 11-14% range, marking them as the thinner, more open branches of the field.
The United States leads with 87 filings among the receiving offices tracked, followed by the European Patent Office at 69 and the WIPO/PCT route at 36. India (27), China (23) and Canada (19) trail behind, indicating that most applicants are still routing primary protection through the US and Europe before deciding on secondary jurisdictions. A filer targeting freedom to operate outside the top two offices should check the smaller jurisdictions individually rather than assuming coverage follows the US or EPO filing automatically.
US20160002611A1, filed by the Regents of the University of Minnesota in January 2016, describes a cell-free biosynthesis platform combining a transcription-translation (TX-TL) tool built on modular plasmid libraries with a modular microfluidic architecture for mixing gene units at high throughput. It is used here as the representative record for the field because it captures both defining features of modern cell-free biomanufacturing: enzyme-synthesis control via plasmid stoichiometry and scalable microfluidic handling. Anyone building a cell-free TX-TL system should check their stoichiometry-control and fluidic-handling design against this filing's specific mechanisms before assuming clearance.
Research Cell-Free Biomanufacturing: Cell-Free Metabolic Engineering Patent Landscape in depth with Eureka
Go past this page: query the whole cell-free biomanufacturing: cell-free metabolic engineering patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.